A5068906858- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Chronic Lymphocytic Leukemia Research
- T-cell and Retrovirus Studies
- Glioma Diagnosis and Treatment
- Cerebrospinal fluid and hydrocephalus
- CNS Lymphoma Diagnosis and Treatment
- Vascular Malformations Diagnosis and Treatment
- Nail Diseases and Treatments
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Extracellular vesicles in disease
- Healthcare Policy and Management
- Single-cell and spatial transcriptomics
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders
- Intracranial Aneurysms: Treatment and Complications
- Acute Lymphoblastic Leukemia research
- Spectroscopy and Chemometric Analyses
- Spinal Dysraphism and Malformations
- Neutropenia and Cancer Infections
Johns Hopkins University
2016-2024
Sidney Kimmel Comprehensive Cancer Center
2019-2024
Johns Hopkins Medicine
2016-2024
U-M Rogel Cancer Center
2022
Comprehensive Blood & Cancer Center
2022
Auburn University
2013
Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug conjugate (ADC) which was FDA approved for R/R DLBCL who have received at least 2 prior lines of therapy based on the LOTIS-2 trial. However, there limited data regarding its efficacy real-world setting (RWS). This retrospective study included 21 US centers and evaluated outcomes treated Lonca. Our analysis includes 187 notably higher risk...
ABSTRACT Introduction While the use of internal standard methodology for qNMR is a proven and reliable form quantification, simplified alternative approaches are needed. Agilent's absolute intensity utility software valuable that has not yet been subjected to validation in peer‐reviewed literature. Objective To provide method with specific application natural product quantification by measuring saccharide content açaí materials. Methods In order validate method, calibration test samples...
Summary The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes allogeneic haematopoietic transplantation (allo‐HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated 182 adults (aged ≥18 years) with undergoing allo‐HCT between 2008 2019. Non‐relapse mortality (NRM), disease relapse/progression (REL), progression‐free survival...
e23211 Background: Patients with cancer who develop Pneumocystis pneumonia (PCP) have 30-day mortality rates estimated to be > 50%. Despite consensus guidelines from the American Society of Clinical Oncology (ASCO) and Infectious Diseases America (IDSA), appropriate PCP prophylaxis is reported as low 3.9% for patients solid malignancies on chronic, high-dose corticosteroids. In this trainee-led QI initiative, we investigated at a tertiary care center surveyed clinicians regarding barriers...
319 Background: In a prior trainee-led QI initiative, we surveyed clinicians about Pneumocystis pneumonia (PCP) and assessed rates of appropriate prophylaxis. Through retrospective chart review, found that 47% eligible patients (n=140/297) received PCP prophylaxis between 5/2022 5/2023. Clinician-reported barriers included knowledge gaps, systems-related unclear corticosteroid durations. the current built an order set to facilitate prescription created automated approach assess rates. We...
Patients with relapsed classic Hodgkin lymphomas receive salvage therapy immune checkpoint inhibitors (ICI) or chemotherapy (no-ICI). responding to often undergo consolidation allogeneic blood marrow transplantations (alloBMT). We previously reported that cHL patients treated ICI followed by alloBMT experienced improved 3-year progression-free survival (PFS) compared without ICI, alloBMT. In this retrospective analysis, we report the 5-year OS, PFS, and GVHD incidence in before...
Patients who have radiographically detectable lesions in their brain or other symptoms compatible with tumors pose challenges for diagnosis. The only definitive way to diagnose such patients is through biopsy, an obviously invasive and dangerous procedure. Here we present a new workflow termed "CSF-BAM" that simultaneously identifies
e19045 Background: Mismatched blood or marrow transplantation (BMT) using post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GvHD) prophylaxis has not been well-studied in CTCL. Methods: We analyzed all patients above 18 years old with relapsed/refractory CTCL undergoing mismatched alloBMT. Primary endpoints included disease-free survival (DFS) and overall (OS). Secondary time to neutrophil platelet recovery, GvHD outcomes, day +30 +60 donor chimerism. Results: From...
<title>Abstract</title> While allogeneic blood or marrow transplantation (alloBMT) is an effective therapy for peripheral T-cell lymphoma (PTCL), the optimal approach in this patient population remains to be determined. Here we review outcomes 65 consecutive patients with PTCL who underwent alloBMT non-myeloablative (NMA) conditioning and post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis. The graft source was bone (BM) 46 (71%) (PB) 19 (29%); all BM...
7047 Background: The use of PTCy for graft-versus host-disease (GVHD) prophylaxis has revolutionized alloBMT, but there is limited published experience in PTCL. Methods: All patients with PTCL who received a non-myeloablative alloBMT using PTCy-based GVHD between January 2004 and December 2020 at Johns Hopkins Hospital were analyzed. Standard population statistics used. Results: Sixty-five identified. median age was 59 years (range, 24-75 years). Lymphoma histology included PTCL-not...